Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
about
Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsThe potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapySunitinib: the antiangiogenic effects and beyondClinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Combining targeted agents with modern radiotherapy in soft tissue sarcomas.A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.Clinical Predictors of Survival for Patients with Stage IV Cancer Referred to Radiation OncologyMyeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body RadiotherapySurvival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.Advances in local and ablative treatment of oligometastasis in prostate cancer.Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung CancerThe development of stereotactic body radiotherapy in the past decade: a global perspective.Radiotherapy and immunotherapy: a beneficial liaison?Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesisRobotic Stereotactic Body Radiation Therapy in Patients With Recurrent or Metastatic Abdominopelvic Tumors: A Single Institute Experience.Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy.
P2860
Q26779221-45A0B4F1-77FC-4455-9480-C6E58D27C9CEQ26783291-C9973C7D-DCE1-467A-89E0-57171B1B8596Q28066499-4B4685C2-00A6-402D-B7E7-E82249567EB8Q33633431-D580A709-A6BE-4A23-8FC7-F1F2EED45C1EQ34396047-2A0A580C-432E-495A-A366-0239E8AABCFFQ34687036-CEEC917C-22C5-4A55-A796-471AB683BFC2Q35496632-B5469083-987E-47DA-9DE4-DB750348DE5AQ36483105-FC6FC987-5691-4D5E-A28B-98483B302318Q37427531-8A05CB4C-AA81-4146-92F5-71CBC01ED7FCQ38172209-91AABAFB-FE00-49FD-801B-25E771FD85CEQ38243113-30BD8935-02E9-47D6-8E18-47F3F4D4A9A4Q38880324-B181FC9D-A62A-4DC3-8037-2EF226EE17D0Q38967475-E8C7C5FE-DACC-4753-865A-5293ED9DC365Q39017268-23271E86-E552-4470-8A67-B42862B92493Q41150956-B9E2A41D-DFFD-4644-A699-5602F3431F9BQ46091107-2437CDDE-B030-433A-AE95-9D2CC6D8DA6EQ52591818-BCC845A2-D838-4714-A156-66F175BCD4CAQ53701730-2764B77B-8F91-49EB-9387-2D2CB8BDA5DE
P2860
Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Concurrent sunitinib and stere ...... a prospective clinical trial.
@ast
Concurrent sunitinib and stere ...... a prospective clinical trial.
@en
type
label
Concurrent sunitinib and stere ...... a prospective clinical trial.
@ast
Concurrent sunitinib and stere ...... a prospective clinical trial.
@en
prefLabel
Concurrent sunitinib and stere ...... a prospective clinical trial.
@ast
Concurrent sunitinib and stere ...... a prospective clinical trial.
@en
P2093
P2860
P1433
P1476
Concurrent sunitinib and stere ...... f a prospective clinical trial
@en
P2093
Chien-Ting Chen
Johnny Kao
Max W Sung
Myron Schwartz
Shu-Hsia Chen
Stuart H Packer
P2860
P2888
P304
P356
10.1007/S11523-013-0280-Y
P577
2013-05-10T00:00:00Z